AMAG AMAG Pharmaceuticals Inc.
NewsSee all news
-
AMAG Pharmaceuticals to Present at Upcoming Investor Conferences
WALTHAM, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will participate in the following investor conferences: Jefferies 2019 London
-
AMAG Pharmaceuticals Announces Third Quarter 2019 Financial Results and Provides Corporate Update
Commercial products achieve strong revenue and market share performance Vyleesi™ (bremelanotide injection) launched nationally in September Committed to work with the FDA to keep Makena available for at-risk pregnant
-
AMAG Reports on FDA Advisory Committee Meeting for Makena® (Hydroxyprogesterone Caproate Injection)
WALTHAM, Mass., Oct. 29, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the U.S. Food and Drug Administration's (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee met to
-
AMAG Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee Meeting to Discuss the Results of the Makena PROLONG Trial
WALTHAM, Mass., Oct. 29, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that NASDAQ has halted trading of the company's common stock. The U.S. Food and Drug Administration (FDA) Bone,
-
AMAG Pharmaceuticals Announces the Publication of the PROLONG Trial Evaluating 17-OHPC in the American Journal of Perinatology
WALTHAM, Mass., Oct. 25, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that the results of PROLONG (Progestin's Role in Optimizing Neonatal Gestation) were published online in the
Drug Information
Drug catalyst information is displayed when you hover over / tap on the stage bar graph.
Latest News
-
AMAG Pharmaceuticals to Present at Upcoming Investor Conferences
WALTHAM, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will participate in the following investor conferences: Jefferies 2019 London
-
AMAG Pharmaceuticals Announces Third Quarter 2019 Financial Results and Provides Corporate Update
Commercial products achieve strong revenue and market share performance Vyleesi™ (bremelanotide injection) launched nationally in September Committed to work with the FDA to keep Makena available for at-risk pregnant
-
AMAG Reports on FDA Advisory Committee Meeting for Makena® (Hydroxyprogesterone Caproate Injection)
WALTHAM, Mass., Oct. 29, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the U.S. Food and Drug Administration's (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee met to
-
AMAG Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee Meeting to Discuss the Results of the Makena PROLONG Trial
WALTHAM, Mass., Oct. 29, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that NASDAQ has halted trading of the company's common stock. The U.S. Food and Drug Administration (FDA) Bone,
-
AMAG Pharmaceuticals Announces the Publication of the PROLONG Trial Evaluating 17-OHPC in the American Journal of Perinatology
WALTHAM, Mass., Oct. 25, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that the results of PROLONG (Progestin's Role in Optimizing Neonatal Gestation) were published online in the
-
AMAG Pharmaceuticals Announces Settlement Agreement with Caligan Partners LP
WALTHAM, Mass., Oct. 08, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) ("AMAG") today announced that it has entered into a settlement agreement with Caligan Partners LP ("Caligan"). As part of this
-
Caligan Partners Issues Letter to AMAG Shareholders
AMAG's Recent Public Letter Demonstrates Complete Disregard for Shareholders Current Board's Poor Decisions, Strategic Missteps and Lax Oversight Have Destroyed $1.1 Billion in Shareholder Value over Past Seven Years
-
AMAG Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference
WALTHAM, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) will participate in the Cantor Fitzgerald Global Healthcare Conference in New York on Thursday, October 3, 2019. Ted Myles,
-
AMAG Files Definitive Consent Revocation Statement and Sends Letter to Shareholders
Details Caligan Partners' Reckless Business Ideas and Inexperienced Director Nominees Urges Shareholders to Sign and Return AMAG's GREEN Consent Revocation Card WALTHAM, Mass., Sept. 23, 2019 (GLOBE NEWSWIRE) -- AMAG
-
Caligan Partners Launches Consent Solicitation Process and Sends Letter to AMAG Shareholders
Believes Removal of Four Incumbent Directors is Necessary to Stop Value Destruction at AMAG Caligan's Four Highly-Qualified Nominees Have the Experience and Skillsets Needed to Conduct Comprehensive Review of
-
AMAG Sends Letter to Shareholders
WALTHAM, Mass., Sept. 12, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) ("AMAG" or the "Company") today issued the following letter, which will be mailed to its shareholders. AMAG's Board urges all
-
AMAG Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
WALTHAM, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) will participate in the Morgan Stanley Global Healthcare Conference on Tuesday, September 10, 2019. Bill Heiden, president and
-
AMAG Urges Stockholders to Take No Action on Caligan Partners' Consent Solicitation Materials
WALTHAM, Mass., Sept. 04, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) ("AMAG" or the "Company") today responded to the preliminary consent solicitation filed by Caligan Partners ("Caligan") with
-
AMAG Pharmaceuticals Announces Commercial Availability of Vyleesi™ (Bremelanotide Injection)
The First FDA-Approved As-Needed Treatment for Premenopausal Women Experiencing Low Sexual Desire and Associated Distress Now Available to Patients WALTHAM, Mass., Aug. 27, 2019 (GLOBE NEWSWIRE) -- AMAG